ditert-butyl (2S)-2-methylpentanedioate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ditert-butyl (2S)-2-methylpentanedioate
• 化学式: C₁₄H₂₆O₄
• 分子量: 258.35
• InChiKey: CQVDMPWAXMBUCF-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• NOVEL PRECURSORS OF GLUTAMATE DERIVATIVES
  申请人：Hultsch Christina

  公开号：US20140243532A1

  公开（公告）日：2014-08-28

  This invention relates to novel precursors suitable for 18 F radiolabeling of glutamate derivatives, methods for preparing such compounds and its intermediates, compositions comprising such compounds, kits comprising such compounds or compositions and methods for 18 F radiolabeling of glutamate derivatives wherein the obtained 18 F radiolabeled glutamate derivatives are suitable for diagnostic imaging by Positron Emission Tomography (PET) of proliferative diseases e.g. tumor in mammals.

  本发明涉及适用于18F标记谷氨酸衍生物的新型前体，制备这种化合物及其中间体的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及18F标记谷氨酸衍生物的方法，其中所得的18F标记谷氨酸衍生物适用于通过正电子发射断层扫描（PET）对哺乳动物中的增生性疾病例如肿瘤进行诊断成像。
• HETERODIMERS OF GLUTAMIC ACID
  申请人：Molecular Insight Pharmaceuticals, Inc.

  公开号：EP2097111B1

  公开（公告）日：2015-07-15
• CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
  申请人：ENDOCYTE, INC.

  公开号：US20160361376A1

  公开（公告）日：2016-12-15

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
• Heterodimers of Glutamic Acid
  申请人：Molecular Insight Pharmaceuticals, Inc.

  公开号：US20170044098A1

  公开（公告）日：2017-02-16

  Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH 2 )p Y is C(O), O, NR′S, S(O) 2 , C(O) 2 (CH 2 )p Z is H or C 1- C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 6 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
• US9000037B2
  申请人：——

  公开号：US9000037B2

  公开（公告）日：2015-04-07